These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17343775)

  • 1. Mechanisms of the components of the metabolic syndrome that predispose to diabetes and atherosclerotic CVD.
    Eckel RH
    Proc Nutr Soc; 2007 Feb; 66(1):82-95. PubMed ID: 17343775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease.
    Reaven GM
    Panminerva Med; 2005 Dec; 47(4):201-10. PubMed ID: 16489319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The dysmetabolic syndrome, insulin resistance and increased cardiovascular (CV) morbidity and mortality in type 2 diabetes: aetiological factors in the development of CV complications.
    Eschwège E
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S19-27. PubMed ID: 14502097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolism and insulin signaling in common metabolic disorders and inherited insulin resistance.
    Højlund K
    Dan Med J; 2014 Jul; 61(7):B4890. PubMed ID: 25123125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between adiponectin levels, the metabolic syndrome, and type 2 diabetes: a literature review.
    Frankenberg ADV; Reis AF; Gerchman F
    Arch Endocrinol Metab; 2017 Dec; 61(6):614-622. PubMed ID: 29412387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should the insulin resistance syndrome be treated in the elderly?
    Grant RW; Meigs JB
    Drugs Aging; 2004; 21(3):141-51. PubMed ID: 14979733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of increasing body mass index on cardio-metabolic risk and biomarkers of oxidative stress and inflammation in nascent metabolic syndrome.
    Pahwa R; Adams-Huet B; Jialal I
    J Diabetes Complications; 2017 May; 31(5):810-813. PubMed ID: 28285929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Nutrition and metabolic syndrome].
    Matía Martín P; Lecumberri Pascual E; Calle Pascual AL
    Rev Esp Salud Publica; 2007; 81(5):489-505. PubMed ID: 18274353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients.
    Forst T; Hohberg C; Pfützner A
    Horm Metab Res; 2009 Feb; 41(2):123-31. PubMed ID: 19214922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular disease under the influence of excess visceral fat.
    Després JP
    Crit Pathw Cardiol; 2007 Jun; 6(2):51-9. PubMed ID: 17667865
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adiponectin: A potential therapeutic target for metabolic syndrome.
    Ghadge AA; Khaire AA; Kuvalekar AA
    Cytokine Growth Factor Rev; 2018 Feb; 39():151-158. PubMed ID: 29395659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypertriglyceridemia secondary to obesity and diabetes.
    Subramanian S; Chait A
    Biochim Biophys Acta; 2012 May; 1821(5):819-25. PubMed ID: 22005032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolic syndrome.
    Reaven P
    J Insur Med; 2004; 36(2):132-42. PubMed ID: 15301226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.
    Nesto RW
    Am J Cardiovasc Drugs; 2005; 5(6):379-87. PubMed ID: 16259526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diabetes and branched-chain amino acids: What is the link?
    Bloomgarden Z
    J Diabetes; 2018 May; 10(5):350-352. PubMed ID: 29369529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Pathogenic role of hyperinsulinism in macroangiopathy. Epidemiological data].
    Valensi P
    Presse Med; 1992 Sep; 21(28):1307-11. PubMed ID: 1438099
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of insulin resistance on risk of type 2 diabetes and cardiovascular disease in people with metabolic syndrome.
    Meigs JB; Rutter MK; Sullivan LM; Fox CS; D'Agostino RB; Wilson PW
    Diabetes Care; 2007 May; 30(5):1219-25. PubMed ID: 17259468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Diabetic dyslipidaemia and the atherosclerosis].
    Márk L; Dani G
    Orv Hetil; 2016 May; 157(19):746-52. PubMed ID: 27133274
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
    Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
    Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic insulin resistance, metabolic syndrome and cardiovascular disease.
    Meshkani R; Adeli K
    Clin Biochem; 2009 Sep; 42(13-14):1331-46. PubMed ID: 19501581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.